Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Federico Mensa"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 463-466 (2024)
SummaryWhat are variant-adapted COVID-19 vaccines?The COVID-19 vaccine developed by BioNTech and Pfizer is known as BNT162b2 (Comirnaty). BNT162b2 contains messenger RNA, or mRNA, from SARS-CoV-2. SARS-CoV-2 is the virus responsible for COVID-19. mRN
Externí odkaz:
https://doaj.org/article/e8b9fb9ff1ce495f93b7bf1e5041989b
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 650-661 (2023)
Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein.
Externí odkaz:
https://doaj.org/article/56fce6bdb2dd4c19a17fa7e350c43bbf
Autor:
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin
Publikováno v:
Vaccines, Vol 12, Iss 7, p 734 (2024)
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included health
Externí odkaz:
https://doaj.org/article/4918551c78fb4b61aeeec58f4aba83f5
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 593-605 (2023)
Abstract The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampi
Externí odkaz:
https://doaj.org/article/c8d2ac0c5e80402cb6aa8b2090098c0f
Autor:
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin
Publikováno v:
Vaccines, Vol 12, Iss 2, p 118 (2024)
Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of an ongoing, open-label, phase 2/3 study of monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg d
Externí odkaz:
https://doaj.org/article/37ba4c9bf2d9424caf31c4184fb3a07c
Autor:
Tram T. Tran, Darshan Mehta, Federico Mensa, Caroline Park, Yanjun Bao, Yuri Sanchez Gonzalez
Publikováno v:
Infectious Diseases and Therapy, Vol 7, Iss 4, Pp 473-484 (2018)
Abstract Introduction Chronic hepatitis C (CHC) infection is associated with extrahepatic manifestations (EHMs) which can affect renal, cardiovascular and other comorbidities. The effect of CHC treatment with short-duration regimens on these EHMs is
Externí odkaz:
https://doaj.org/article/5e15028d125f424282c667c719731947
Autor:
Massimo Puoti, Graham Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, SamS Lee, Rui Marinho, Jean-Francois DuFour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Ran Liu, Tami Pilot-Matias, Federico Mensa
Publikováno v:
Journal of Virus Eradication, Vol 3, Iss , Pp 33- (2017)
Externí odkaz:
https://doaj.org/article/d8fdec303da142a0aa0afbed4e240667
Autor:
Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa
Publikováno v:
Journal of Virus Eradication, Vol 3, Iss , Pp 28-29 (2017)
Externí odkaz:
https://doaj.org/article/e8b86e78ccb6479781ccf2ce25c15a49
Autor:
Teresa I. Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric J. Lawitz, Jens Kort, Christine Collins
Publikováno v:
Viruses, Vol 10, Iss 9, p 462 (2018)
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3
Externí odkaz:
https://doaj.org/article/270ad57d0b044800b8e572e7fac70c22